SCHEMBL13429106

SCHEMBL13429106

COc1ccccc1Oc1cc(=O)[nH]c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.53
MEN1 O00255 5/20 0.53
GFER P55789 1/20 0.53
TNKS2 Q9H2K2 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
ABCG2 Q9UNQ0 2/20 0.51
NQO2 P16083 1/20 0.51
KDM4E B2RXH2 4/20 0.51
ATM Q13315 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.48
ALDH1A1 P00352 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
IGF1R P08069 1/20 0.46
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2799080 0.89 TNKS2 (0.61) KMT2AMEN1GFERTNKS2CYP1A2
SCHEMBL31664571 0.89 TNKS2 (0.61) KMT2AMEN1GFERTNKS2CYP1A2
SCHEMBL13429105 0.84 TNKS2 (0.62) KMT2AMEN1GFERTNKS2CYP1A2
SCHEMBL13429062 0.83 L3MBTL1 (0.60) KMT2AMEN1GFERTNKS2CYP1A2
SCHEMBL13429142 0.81 CYP1A2 (0.49) KMT2AMEN1GFERTNKS2CYP1A2
SCHEMBL13429044 0.81 CYP1A2 (0.49) KMT2AMEN1GFERTNKS2CYP1A2
SCHEMBL13429074 0.81 ABCG2 (0.51) KMT2AMEN1TNKS2CYP1A2CYP2C19
SCHEMBL3202433 0.81 CYP1A2 (0.45) KMT2AMEN1GFERTNKS2CYP1A2
SCHEMBL8987152 0.79 TNKS2 (0.59) KMT2AMEN1GFERTNKS2CYP1A2
SCHEMBL2008835 0.79 HPGD (0.54) KMT2AMEN1TNKS2CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA KMT2A 2445/4885MEN1 2648/4885GFER 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.